- GlobeNewswire•16 hours ago
CHAPEL HILL, N.C., March 29, 2017-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical ...
Cempra stock tumbles as it withdraws the marketing application for pneumonia drug in the EU.
- American City Business Journals•2 days ago
Amid a 67 percent workforce reduction following the U.S. Food and Drug Administration’s rejection of its pneumonia drug, solithromycin, Chapel Hill-based Cempra (CEMP) is pulling back on its plans to launch the drug in Europe. The company announced Tuesday that it has withdrawn its marketing authorization application (MAA) aimed at approval from the European Medicines Agency (EMA) for the drug to treat community-acquired pneumonia in adult patients. “We believe the most efficient path to approval is to withdraw the MAA at this time and to resubmit it with the additional data requested by the FDA,” said David Zaccardelli, acting chief executive officer of Cempra, in a statement.
CEMP : Summary for Cempra, Inc. - Yahoo Finance
Cempra, Inc. (CEMP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||3.90 x 5000|
|Ask||3.95 x 1600|
|Day's Range||3.85 - 4.18|
|52 Week Range||2.55 - 26.95|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.66|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|